Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 30

1.

Development and validation of a LC-MS/MS method for the quantification of the checkpoint kinase 1 inhibitor SRA737 in human plasma.

Zangarini M, Berry P, Sludden J, Raynaud FI, Banerji U, Jones P, Edwards D, Veal GJ.

Bioanalysis. 2017 Jul;9(13):1001-1010. doi: 10.4155/bio-2017-0043. Epub 2017 Jul 10.

PMID:
28692309
2.

Pharmacogenetic association of MBL2 and CD95 polymorphisms with grade 3 infection following adjuvant therapy for breast cancer with doxorubicin and cyclophosphamide.

Jamieson D, Sunter N, Muro S, Pouché L, Cresti N, Lee J, Sludden J, Griffin MJ, Allan JM, Verrill MW, Boddy AV.

Eur J Cancer. 2017 Jan;71:15-24. doi: 10.1016/j.ejca.2016.10.035. Epub 2016 Dec 8.

PMID:
27940354
3.

A phase I pharmacokinetic and pharmacodynamic study of the oral mitogen-activated protein kinase kinase (MEK) inhibitor, WX-554, in patients with advanced solid tumours.

Jamieson D, Griffin MJ, Sludden J, Drew Y, Cresti N, Swales K, Merriman M, Allen R, Bevan P, Buerkle M, Mala C, Coyle V, Rodgers L, Dean E, Greystoke A, Banerji U, Wilson RH, Evans TR, Anthoney A, Ranson M, Boddy AV, Plummer R.

Eur J Cancer. 2016 Nov;68:1-10. doi: 10.1016/j.ejca.2016.08.026. Epub 2016 Sep 28.

PMID:
27693888
4.

Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly(ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancer.

Drew Y, Ledermann J, Hall G, Rea D, Glasspool R, Highley M, Jayson G, Sludden J, Murray J, Jamieson D, Halford S, Acton G, Backholer Z, Mangano R, Boddy A, Curtin N, Plummer R.

Br J Cancer. 2016 Jun 14;114(12):e21. doi: 10.1038/bjc.2016.133. Epub 2016 May 26. No abstract available.

5.

Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly(ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancer.

Drew Y, Ledermann J, Hall G, Rea D, Glasspool R, Highley M, Jayson G, Sludden J, Murray J, Jamieson D, Halford S, Acton G, Backholer Z, Mangano R, Boddy A, Curtin N, Plummer R.

Br J Cancer. 2016 Mar 29;114(7):723-30. doi: 10.1038/bjc.2016.41. Epub 2016 Mar 22. Erratum in: Br J Cancer. 2016 Jun 14;114(12):e21.

6.

Cyclophosphamide pharmacokinetics and pharmacogenetics in children with B-cell non-Hodgkin's lymphoma.

Veal GJ, Cole M, Chinnaswamy G, Sludden J, Jamieson D, Errington J, Malik G, Hill CR, Chamberlain T, Boddy AV.

Eur J Cancer. 2016 Mar;55:56-64. doi: 10.1016/j.ejca.2015.12.007. Epub 2016 Jan 12.

7.

Efficacy of PARP Inhibitor Rucaparib in Orthotopic Glioblastoma Xenografts Is Limited by Ineffective Drug Penetration into the Central Nervous System.

Parrish KE, Cen L, Murray J, Calligaris D, Kizilbash S, Mittapalli RK, Carlson BL, Schroeder MA, Sludden J, Boddy AV, Agar NY, Curtin NJ, Elmquist WF, Sarkaria JN.

Mol Cancer Ther. 2015 Dec;14(12):2735-43. doi: 10.1158/1535-7163.MCT-15-0553. Epub 2015 Oct 5.

8.

Pharmacogenetics of adjuvant breast cancer treatment with cyclophosphamide, epirubicin and 5-fluorouracil.

Jamieson D, Lee J, Cresti N, Jackson R, Griffin M, Sludden J, Verrill M, Boddy AV.

Cancer Chemother Pharmacol. 2014 Oct;74(4):667-74. doi: 10.1007/s00280-014-2541-6. Epub 2014 Jul 24.

PMID:
25055937
9.

Two minor NQO1 and NQO2 alleles predict poor response of breast cancer patients to adjuvant doxorubicin and cyclophosphamide therapy.

Jamieson D, Cresti N, Bray J, Sludden J, Griffin MJ, Hawsawi NM, Famie E, Mould EV, Verrill MW, May FE, Boddy AV.

Pharmacogenet Genomics. 2011 Dec;21(12):808-19. doi: 10.1097/FPC.0b013e32834b6918.

PMID:
21946896
10.

A Phase I clinical study of cisplatin-incorporated polymeric micelles (NC-6004) in patients with solid tumours.

Plummer R, Wilson RH, Calvert H, Boddy AV, Griffin M, Sludden J, Tilby MJ, Eatock M, Pearson DG, Ottley CJ, Matsumura Y, Kataoka K, Nishiya T.

Br J Cancer. 2011 Feb 15;104(4):593-8. doi: 10.1038/bjc.2011.6. Epub 2011 Feb 1.

11.

Influence of pharmacogenetics on response and toxicity in breast cancer patients treated with doxorubicin and cyclophosphamide.

Bray J, Sludden J, Griffin MJ, Cole M, Verrill M, Jamieson D, Boddy AV.

Br J Cancer. 2010 Mar 16;102(6):1003-9. doi: 10.1038/sj.bjc.6605587. Epub 2010 Feb 23.

12.

Phase I study of MG98, an oligonucleotide antisense inhibitor of human DNA methyltransferase 1, given as a 7-day infusion in patients with advanced solid tumors.

Plummer R, Vidal L, Griffin M, Lesley M, de Bono J, Coulthard S, Sludden J, Siu LL, Chen EX, Oza AM, Reid GK, McLeod AR, Besterman JM, Lee C, Judson I, Calvert H, Boddy AV.

Clin Cancer Res. 2009 May 1;15(9):3177-83. doi: 10.1158/1078-0432.CCR-08-2859. Epub 2009 Apr 21.

13.

Pharmacokinetic investigation of imatinib using accelerator mass spectrometry in patients with chronic myeloid leukemia.

Boddy AV, Sludden J, Griffin MJ, Garner C, Kendrick J, Mistry P, Dutreix C, Newell DR, O'Brien SG.

Clin Cancer Res. 2007 Jul 15;13(14):4164-9.

14.

A phase I and pharmacokinetic study of paclitaxel poliglumex (XYOTAX), investigating both 3-weekly and 2-weekly schedules.

Boddy AV, Plummer ER, Todd R, Sludden J, Griffin M, Robson L, Cassidy J, Bissett D, Bernareggi A, Verrill MW, Calvert AH.

Clin Cancer Res. 2005 Nov 1;11(21):7834-40.

15.

Determination of anti-cancer drug actinomycin D in human plasma by liquid chromatography-mass spectrometry.

Veal GJ, Errington J, Sludden J, Griffin MJ, Price L, Parry A, Hale J, Pearson AD, Boddy AV; UKCCSG Pharmacology Working Group.

J Chromatogr B Analyt Technol Biomed Life Sci. 2003 Oct 5;795(2):237-43.

PMID:
14522028
16.

Topotecan in combination with carboplatin: phase I trial evaluation of two treatment schedules.

Simpson AB, Calvert PM, Sludden JA, Boddy AV, Griffin MJ, Schätzlein A, Wilson P, Fishwick K, Wheatley A, Ross GA, Calvert AH, Twelves CJ.

Ann Oncol. 2002 Mar;13(3):399-402.

PMID:
11996470
17.

Pharmacological study of paclitaxel duration of infusion combined with GFR-based carboplatin in the treatment of ovarian cancer.

Boddy AV, Griffin MJ, Sludden J, Thomas HD, Fishwick K, Wright JG, Plumner ER, Highley M, Calvert AH.

Cancer Chemother Pharmacol. 2001 Jul;48(1):15-21.

PMID:
11488519
18.

Reversal of drug resistance in human tumor xenografts by 2'-deoxy-5-azacytidine-induced demethylation of the hMLH1 gene promoter.

Plumb JA, Strathdee G, Sludden J, Kaye SB, Brown R.

Cancer Res. 2000 Nov 1;60(21):6039-44.

19.

Evaluation of dihydropyrimidine dehydrogenase activity in South-west Asian, Kenyan and Ghanaian populations.

Morsman JM, Sludden J, Ameyaw MM, Githang'A J, Indalo A, Ofori-Adjei D, McLeod HL.

Br J Clin Pharmacol. 2000 Sep;50(3):269-72.

20.

The encapsulation of bleomycin within chitosan based polymeric vesicles does not alter its biodistribution.

Sludden J, Uchegbu IF, Schätzlein AG.

J Pharm Pharmacol. 2000 Apr;52(4):377-82.

PMID:
10813546
21.

Phase I and pharmacokinetic study of DACA (XR5000): a novel inhibitor of topoisomerase I and II. CRC Phase I/II Committee.

Twelves CJ, Gardner C, Flavin A, Sludden J, Dennis I, de Bono J, Beale P, Vasey P, Hutchison C, Macham MA, Rodriguez A, Judson I, Bleehen NM.

Br J Cancer. 1999 Aug;80(11):1786-91.

22.

Phase I/pharmacokinetic study of the topoisomerase I inhibitor GG211 administered as a 21-day continuous infusion.

Stevenson JP, DeMaria D, Sludden J, Kaye SB, Paz-Ares L, Grochow LB, McDonald A, Selinger K, Wissel P, O'Dwyer PJ, Twelves C.

Ann Oncol. 1999 Mar;10(3):339-44.

PMID:
10355580
23.

The frequency and distribution of thiopurine methyltransferase alleles in Caucasian and Asian populations.

Collie-Duguid ES, Pritchard SC, Powrie RH, Sludden J, Collier DA, Li T, McLeod HL.

Pharmacogenetics. 1999 Feb;9(1):37-42.

PMID:
10208641
24.

Autoregulation of 5-fluorouracil metabolism.

McLeod HL, Sludden J, Hardy SC, Lock RE, Hawksworth GM, Cassidy J.

Eur J Cancer. 1998 Sep;34(10):1623-7.

PMID:
9893640
25.

Dihydropyrimidine dehydrogenase pharmacogenetics in Caucasian subjects.

Ridge SA, Sludden J, Brown O, Robertson L, Wei X, Sapone A, Fernandez-Salguero PM, Gonzalez FJ, Vreken P, van Kuilenburg AB, van Gennip AH, McLeod HL.

Br J Clin Pharmacol. 1998 Aug;46(2):151-6.

26.

Ethnic differences in catechol O-methyltransferase pharmacogenetics: frequency of the codon 108/158 low activity allele is lower in Kenyan than Caucasian or South-west Asian individuals.

McLeod HL, Syvänen AC, Githang'a J, Indalo A, Ismail D, Dewar K, Ulmanen I, Sludden J.

Pharmacogenetics. 1998 Jun;8(3):195-9.

PMID:
9682265
27.

Polymeric chitosan-based vesicles for drug delivery.

Uchegbu IF, Schätzlein AG, Tetley L, Gray AI, Sludden J, Siddique S, Mosha E.

J Pharm Pharmacol. 1998 May;50(5):453-8.

PMID:
9643437
28.

Liver dihydropyrimidine dehydrogenase activity in human, cynomolgus monkey, rhesus monkey, dog, rat and mouse.

Sludden J, Hardy SC, VandenBranden MR, Wrighton SA, McLeod HL.

Pharmacology. 1998 May;56(5):276-80.

PMID:
9597696
29.

Dihydropyrimidine dehydrogenase pharmacogenetics in patients with colorectal cancer.

Ridge SA, Sludden J, Wei X, Sapone A, Brown O, Hardy S, Canney P, Fernandez-Salguero P, Gonzalez FJ, Cassidy J, McLeod HL.

Br J Cancer. 1998;77(3):497-500.

30.

Characterization of dihydropyrimidine dehydrogenase in human colorectal tumours.

McLeod HL, Sludden J, Murray GI, Keenan RA, Davidson AI, Park K, Koruth M, Cassidy J.

Br J Cancer. 1998;77(3):461-5.

Supplemental Content

Loading ...
Support Center